We are live on ! Find out more
FDMT icon

4D Molecular Therapeutics
FDMT

52 hedge funds and large institutions have $602M invested in 4D Molecular Therapeutics in 2020 Q4 according to their latest regulatory filings, with 52 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

55.09% more ownership

Funds ownership: 0% → 55.09% (+55%)

Holders
52
Holders Change
+52
Holders Change %
–
% of All Funds
0.92%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.02%
New
52
Increased
–
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Viking Global Investors
Viking Global Investors
Connecticut
+$163M
2
Fidelity Investments
Fidelity Investments
Massachusetts
+$65.8M
3
BI
BVF Inc
California
+$45.7M
4
ACH
ArrowMark Colorado Holdings
Colorado
+$43.9M
5
Janus Henderson Group
Janus Henderson Group
United Kingdom
+$42.2M

Top Sellers

No sellers this quarter
Name Holding Trade Value Shares
Change 		Change in
Stake
Viking Global Investors
1
Viking Global Investors
Connecticut
$163M +$163M +3,937,914 New
Fidelity Investments
2
Fidelity Investments
Massachusetts
$66.1M +$65.8M +1,594,355 New
BI
3
BVF Inc
California
$45.8M +$45.7M +1,106,070 New
ACH
4
ArrowMark Colorado Holdings
Colorado
$44.1M +$43.9M +1,063,744 New
Janus Henderson Group
5
Janus Henderson Group
United Kingdom
$39.9M +$42.2M +1,021,911 New
CC
6
Casdin Capital
New York
$32.4M +$32.2M +780,555 New
SM
7
SB Management
United Arab Emirates
$29.8M +$29.6M +717,734 New
PA
8
Perceptive Advisors
New York
$24.9M +$24.8M +600,256 New
Alkeon Capital Management
9
Alkeon Capital Management
New York
$16.7M +$16.6M +401,885 New
OCA
10
Octagon Capital Advisors
New York
$15.7M +$15.6M +377,777 New
Millennium Management
11
Millennium Management
New York
$14.3M +$14.2M +344,283 New
T. Rowe Price Associates
12
T. Rowe Price Associates
Maryland
$14.2M +$14.2M +343,678 New
Morgan Stanley
13
Morgan Stanley
New York
$10.2M +$10.1M +245,705 New
HA
14
HHLR Advisors
Cayman Islands
$9.33M +$9.29M +225,000 New
Wellington Management Group
15
Wellington Management Group
Massachusetts
$8.67M +$8.64M +209,179 New
CAM
16
Cormorant Asset Management
Massachusetts
$8.29M +$8.26M +200,000 New
ABG
17
Ally Bridge Group
New York
$6.22M +$6.19M +150,000 New
DM
18
Deerfield Management
New York
$6.22M +$6.19M +150,000 New
Federated Hermes
19
Federated Hermes
Pennsylvania
$6.22M +$6.19M +150,000 New
O
20
OrbiMed
New York
$5.18M +$5.16M +125,000 New
WP
21
Woodline Partners
California
$4.29M +$4.27M +103,453 New
FCM
22
Farallon Capital Management
California
$4.14M +$4.13M +100,000 New
Goldman Sachs
23
Goldman Sachs
New York
$3.11M +$3.1M +74,978 New
LCM
24
Laurion Capital Management
New York
$2.4M +$2.39M +58,000 New
Citadel Advisors
25
Citadel Advisors
Florida
$2.17M +$2.17M +52,463 New
1
2 3

FDMT Hedge Fund Activity: Q4 2020 in Review

52 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in 4D Molecular Therapeutics (FDMT) for Q4 2020, worth a combined $602M.

Buyers outnumbered sellers: 52 funds opened new FDMT positions and 0 closed out — a net gain of 52 holders — while 0 added to existing stakes and 0 trimmed.

The largest buyer was Viking Global Investors, opening a new position worth an estimated $163M.

  • 52 institutional investors held 4D Molecular Therapeutics (FDMT) as of Q4 2020, up from 0 in Q3 2020.
  • Funds reported $602M of 4D Molecular Therapeutics stock for Q4 2020.
  • 52 funds opened new 4D Molecular Therapeutics positions in Q4 2020 and 0 closed out, a net change of +52 holders.
  • The largest 4D Molecular Therapeutics buyer in Q4 2020 was Viking Global Investors, an estimated $163M added.

Based on aggregated 13F filings for Q4 2020.